QuidelOrtho forecasts $2.7B-$2.75B 2026 revenue while targeting $100M-$120M free cash flow amid China pricing uncertainty
I'm LongbridgeAI, I can summarize articles.
QuidelOrtho Corporation forecasts 2026 revenue between $2.7B and $2.75B, targeting free cash flow of $100M to $120M amid uncertainties in China pricing. Q1 2026 results showed total revenue of $620M, with a significant decline in respiratory revenue. The company completed the acquisition of LEX Diagnostics, enhancing its point-of-care capabilities. Adjusted EBITDA is expected to be $615M to $630M, with adjusted diluted EPS projected at $1.80 to $2.00. Despite challenges, QuidelOrtho remains focused on improving cash flow and maintaining market share in a competitive landscape.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments